Progression of chronic obstructive pulmonary disease: impact of inflammation, comorbidities and therapeutic intervention

ABSTRACT

Background and aim: Chronic obstructive pulmonary disease (COPD) is a major cause of morbidity and mortality, and through under-diagnosis, is often inappropriately treated. This multicomponent disease involves both airway and systemic inflammation at all stages and may influence the progression of disease and the pathophysiology of comorbidities. This review examines evidence linking inflammation, disease progression and comorbidities in COPD, and the potential role of anti-inflammatory therapies.

Methods: Systematic searches of Medline and Cochrane Reviews databases from 1976 to March 2008 using the terms: chronic obstructive pulmonary disease, disease progression, inflammation, inflammatory, comorbid condition, comorbidity, treatment, therapy, bronchodilator, inhaled corticosteroid.

Findings: Increased levels of interleukin-8, tumour necrosis factor-alpha and systemic C-reactive protein correlate with worse disease severity, exacerbation rates and lung function decline. Increased systemic C-reactive protein is also associated with poorer health status and comorbidities (e.g. cardiovascular disease, cancer and skeletal muscle dysfunction). The pivotal role of inflammation in the pathogenesis of COPD and its comorbidities suggests anti-inflammatory therapies will be important in the overall management of COPD. Long-term studies indicate that combination therapies consisting of a long-acting beta-agonist plus an inhaled corticosteroid in one inhaler have the potential to modify disease progression through positive effects on lung function, exacerbations, symptoms and health status. The TOwards a Revolution in COPD Health (TORCH) study is the first to demonstrate that a COPD pharmacotherapy (combination salmeterol plus fluticasone propionate) significantly decreased the rate of lung function decline versus placebo.

Conclusion: Better understanding of the specific inflammatory mechanisms underlying COPD disease progression and associated comorbidities will likely lead to more effective management of the disease.

Key words: :

• Chronic obstructive pulmonary disease
• Comorbidity
• Disease progression
• Inflammation
• Inhaled corticosteroid
• Long-acting beta-agonist

Acknowledgements

Declaration of interest: Robert A. Stockley has received grant funding (non-commercial) from Talecris; fees for attending advisory boards by AstraZeneca, Boehringer Ingelheim, GlaxoSmithKline, Schering-Plough and Talecris; lectures fees from GlaxoSmithKline and Talecris; and travel expenses from Boehringer Ingelheim.

Medical writing support by Jagdish Devalia and David Cutler of Gardiner-Caldwell Communications is kindly acknowledged; this support was funded by GlaxoSmithKline.